LabConnect announced the grand opening of its new facility in Wuxi, China. Together with LabConnect's laboratory capabilities in Australia, the new site strengthens the company's ability to support multi-regional clinical trials while helping Asia-Pacific pharmaceutical, biotechnology and clinical research organizations expand their research programs globally.
Fully integrated into LabConnect's global infrastructure, the Wuxi facility enables study teams to operate across regions with unified data, consistent operational oversight and advanced sample logistics and handling procedures.
The facility was developed in collaboration with Teddy Laboratory, now part of Frontage Laboratories, combining Teddy Laboratory's local laboratory expertise with LabConnect's global central laboratory services, logistics capabilities, and technology-driven decentralized network model.
"This facility reflects LabConnect's continued investment in building the global services needed to support clinical trials today and the next generation of clinical research," said Wes Wheeler, Chief Executive Officer of LabConnect. "We are proud to offer China-based capabilities and a global service network that supports both multinational pharmaceutical and biotechnology companies entering China and Chinese companies expanding into international markets."
The Wuxi facility will support a range of clinical trial services, including custom kit building, advanced sample tracking and logistics, and biorepository services, all designed to meet international regulatory standards.